J
James F. Rooney
Researcher at National Institutes of Health
Publications - 115
Citations - 17023
James F. Rooney is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Emtricitabine & Pre-exposure prophylaxis. The author has an hindex of 46, co-authored 105 publications receiving 14731 citations. Previous affiliations of James F. Rooney include University of California, San Diego & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant,Javier R. Lama,Peter L. Anderson,Vanessa McMahan,Albert Y. Liu,Lorena Vargas,Pedro Goicochea,Martin Casapia,Juan Vicente Guanira-Carranza,Maria Esther Ramirez-Cardich,Orlando Montoya-Herrera,Telmo Fernandez,Valdilea G. Veloso,Susan Buchbinder,Suwat Chariyalertsak,Mauro Schechter,Linda-Gail Bekker,Kenneth H. Mayer,Esper G. Kallas,K. Rivet Amico,Kathleen Mulligan,Lane R. Bushman,Robert J. Hance,Carmela Ganoza,Patricia Defechereux,Brian S. Postle,Furong Wang,J. Jeff McConnell,Jia-Hua Zheng,Jeanny Lee,James F. Rooney,Howard S. Jaffe,Ana Martinez,David N. Burns,David V. Glidden +34 more
TL;DR: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects and Detectable blood levels strongly correlated with the prophylactic effect.
Journal ArticleDOI
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Sheena McCormack,David Dunn,Monica Desai,David Dolling,Mitzy Gafos,Richard Gilson,Richard Gilson,Ann Sullivan,Amanda Clarke,Iain Reeves,Gabriel Schembri,Nicola Mackie,Christine Bowman,Charles J.N. Lacey,Vanessa Apea,Michael Brady,Julie Fox,Stephen Taylor,Simone Antonucci,Saye Khoo,James F. Rooney,Anthony Nardone,Martin Fisher,Alan McOwan,Andrew N. Phillips,Anne M Johnson,Brian Gazzard,ON Gill +27 more
TL;DR: In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting.
Journal ArticleDOI
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne M. Marrazzo,Gita Ramjee,Barbra A. Richardson,Kailazarid Gomez,Nyaradzo Mgodi,Gonasagrie Nair,Thesla Palanee,Clemensia Nakabiito,Ariane van der Straten,Lisa M. Noguchi,Craig W. Hendrix,James Y. Dai,S. Ganesh,Baningi Mkhize,Marthinette Taljaard,Urvi M. Parikh,Jeanna M. Piper,Benoît Mâsse,Benoît Mâsse,Cynthia I. Grossman,James F. Rooney,Jill L. Schwartz,Heather Watts,Mark A. Marzinke,Sharon L. Hillier,Ian McGowan,Z. Mike Chirenje +26 more
TL;DR: None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low.
Journal ArticleDOI
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Robert M. Grant,Robert M. Grant,Robert M. Grant,Peter L. Anderson,Vanessa McMahan,Albert Y. Liu,K. Rivet Amico,Megha Mehrotra,Sybil G. Hosek,Carlos Mosquera,Martin Casapia,Orlando Montoya,Susan Buchbinder,Valdilea G. Veloso,Kenneth H. Mayer,Suwat Chariyalertsak,Linda-Gail Bekker,Esper G. Kallas,Mauro Schechter,Juan V. Guanira,Lane R. Bushman,David N. Burns,James F. Rooney,David V. Glidden +23 more
TL;DR: The effect of PrEP is increased by greater uptake and adherence during periods of higher risk, and drug concentrations in dried blood spots are strongly correlated with protective benefit.
Journal ArticleDOI
Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
Rhoda S. Sperling,David Shapiro,Robert W. Coombs,John Todd,Steven A. Herman,George D. McSherry,Mary Jo O'Sullivan,Russell B. Van Dyke,Eleanor Jimenez,Christine Rouzioux,Patricia M. Flynn,John L. Sullivan,Stephen A. Spector,Clemente Diaz,James F. Rooney,James Balsley,Richard D. Gelber,Edward M. Connor +17 more
TL;DR: A placebo-controlled trial has shown that treatment with zidovudine reduces the rate at which human immunodeficiency virus type 1 (HIV-1) is transmitted from mother to infant as discussed by the authors.